DE60329668D1 - Verfahren zur unterdrückung der ptx3 genexpression - Google Patents

Verfahren zur unterdrückung der ptx3 genexpression

Info

Publication number
DE60329668D1
DE60329668D1 DE60329668T DE60329668T DE60329668D1 DE 60329668 D1 DE60329668 D1 DE 60329668D1 DE 60329668 T DE60329668 T DE 60329668T DE 60329668 T DE60329668 T DE 60329668T DE 60329668 D1 DE60329668 D1 DE 60329668D1
Authority
DE
Germany
Prior art keywords
sup
sub
suppressing
gene expression
ptx
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60329668T
Other languages
English (en)
Inventor
Shigeru Morikawa
Akashi Izumi
Takao Hamakubo
Tatsuhiko Kodama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kowa Co Ltd
Nissan Chemical Corp
Original Assignee
Kowa Co Ltd
Nissan Chemical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co Ltd, Nissan Chemical Corp filed Critical Kowa Co Ltd
Application granted granted Critical
Publication of DE60329668D1 publication Critical patent/DE60329668D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
DE60329668T 2002-04-15 2003-04-11 Verfahren zur unterdrückung der ptx3 genexpression Expired - Lifetime DE60329668D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37211402P 2002-04-15 2002-04-15
US10/196,428 US20030195167A1 (en) 2002-04-15 2002-07-17 PTX3-gene expression inhibitor
PCT/JP2003/004603 WO2003086380A1 (en) 2002-04-15 2003-04-11 Ptx3 gene expression suppressing method

Publications (1)

Publication Number Publication Date
DE60329668D1 true DE60329668D1 (de) 2009-11-26

Family

ID=28794074

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60329668T Expired - Lifetime DE60329668D1 (de) 2002-04-15 2003-04-11 Verfahren zur unterdrückung der ptx3 genexpression

Country Status (9)

Country Link
US (2) US20030195167A1 (de)
EP (1) EP1494661B1 (de)
JP (1) JP4409295B2 (de)
AT (1) ATE445395T1 (de)
AU (1) AU2003226456A1 (de)
DE (1) DE60329668D1 (de)
MY (1) MY137134A (de)
TW (1) TWI349547B (de)
WO (1) WO2003086380A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060276486A1 (en) * 2003-04-17 2006-12-07 Kowa Co., Ktd. Lklf/klf2 gene expression promoter
US8415364B2 (en) 2003-11-26 2013-04-09 Duke University Method of preventing or treating glaucoma
ITRM20030596A1 (it) * 2003-12-23 2005-06-24 Sigma Tau Ind Farmaceuti Uso di inibitori della pentraxina lunga ptx3, per la preparazione di un medicamento per la prevenzione e cura di patologie che rispondono all'inibizione dell'attivita' biologica di detta ptx3.
JP4667372B2 (ja) * 2004-02-25 2011-04-13 株式会社ペルセウスプロテオミクス 血管障害の程度の判定方法
EP1740164B1 (de) * 2004-04-26 2008-08-13 Alcon Inc. Statine zur behandlung von okularer hypertonie und glaukom
WO2008001499A1 (fr) * 2006-06-29 2008-01-03 Kowa Co., Ltd. Agent prophylactique et/ou thérapeutique pour le traitement de la polyarthrite rhumatoïde
CN106950366B (zh) * 2017-02-15 2019-03-22 中国医学科学院北京协和医院 一种acpa阴性的ra诊断标志物及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5244916A (en) * 1992-01-31 1993-09-14 The Scripps Research Institute Inhibition of respiratory burst using posttranslational modification inhibitors
WO1999026657A1 (en) * 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
JP2002539108A (ja) * 1999-03-08 2002-11-19 メルク エンド カムパニー インコーポレーテッド 結晶質水和ジヒドロキシオープンアシッドシンバスタチンカルシウム塩
US6403637B1 (en) * 1999-08-09 2002-06-11 Univ Saint Louis Methods of modulating matrix metalloproteinase activity and uses thereof
US20030018040A1 (en) * 2000-02-10 2003-01-23 Yasuo Sugiyama Tnf-alpha inhibitors
AU2002210521A1 (en) * 2000-09-19 2002-04-02 Novimmune S.A. Use of statins (HMG-CoA reductase inhibitors) for the preparation of medicament as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent
US20020159974A1 (en) * 2000-09-19 2002-10-31 Francois Mach Treatment of multiple sclerosis with statins (HMG-CoA reductase inhibitors)

Also Published As

Publication number Publication date
AU2003226456A8 (en) 2003-10-27
ATE445395T1 (de) 2009-10-15
JP4409295B2 (ja) 2010-02-03
AU2003226456A1 (en) 2003-10-27
WO2003086380A1 (en) 2003-10-23
JP2005522490A (ja) 2005-07-28
MY137134A (en) 2008-12-31
TWI349547B (en) 2011-10-01
EP1494661B1 (de) 2009-10-14
TW200403990A (en) 2004-03-16
US20080161348A1 (en) 2008-07-03
EP1494661A1 (de) 2005-01-12
US20030195167A1 (en) 2003-10-16

Similar Documents

Publication Publication Date Title
TW200519088A (en) Aryl or heteroaryl amide compounds
EA200601830A1 (ru) Ортозамещённые арильные или гетероарильные амидные соединения
EA200601847A1 (ru) Замещённые метиларил- или гетероариламидные соединения
DE60301345D1 (de) Stabilisierte askorbinsäurederivate
WO2005089256A3 (en) Antiangiogenic agents
ATE201687T1 (de) Galanthamin-derivat, ein verfahren zu seiner herstellung und seine verwendung als medikament
ATE402185T1 (de) Verfahren für fluorcytidinderivate
DE60329668D1 (de) Verfahren zur unterdrückung der ptx3 genexpression
ATE207055T1 (de) Verfahren zur herstellung von 4-aryl-3- hydroxymethyl-piperidinen
WO2004080408A3 (en) Method of treating cancer with azaspirane compositions
PL235835A1 (de)
DE602004020667D1 (en) Prostaglandinsynthese
ATE239701T1 (de) Polyethoxylierte retinamid-derivate und verfahren zu ihrer herstellung
DE602004013365D1 (de) Verfahren zur modifizierung eines fluorpolymersubstrats und dadurch erhaltene verbundgegenstände
RS20050937A (en) Resolution of alpha- (phenoxy)phenylacetic acid derivatives
ATE447728T1 (de) Lichtempfindliche verbindung und lichtempfindliches harz
DE60314167D1 (de) Verfahren zur herstellung von fluorhalogenalkanen
ATE202080T1 (de) Verfahren zur herstellung von 2-cyanobiphenyl verbindungen
DE602004030091D1 (de) Verfahren zur reduktiven deshalogenierung
DK0504290T3 (da) Inhibitorer af dihydrofylatreduktase fra Pneumocystis carinii
DE602004020050D1 (de) Verfahren zur herstellung substituierter imidazolderivate und in dem verfahren verwendete zwischenprodukte
ATE312107T1 (de) Verfahren zur herstellung von alkyllithium- verbindungen
BRPI0412505A (pt) processo para preparar organohidrogensiloxanos cìclicos
TW200510271A (en) Alkynyl substituded condensed heterocyclic compound, method for producing the same and organic electroluminescence element using the same
MY142362A (en) Pharmaceutical composition for promoting angiogenesis

Legal Events

Date Code Title Description
8364 No opposition during term of opposition